The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen
- PMID: 15575931
- DOI: 10.1111/j.1398-9995.2004.00612.x
The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen
Abstract
Background: The allergen-induced early asthmatic response [provocation concentration (PC)20, the concentration causing a 20% forced expiratory volume in 1 s (FEV)1 fall] depends on the level of IgE sensitivity and the degree of nonallergic airway hyperresponsiveness (AHR) and can be predicted from histamine PC20 and allergen skin test endpoint.
Objectives: We examined the relationships between allergen PC20, methacholine PC20, and allergen skin test endpoint and assessed the accuracy of both the histamine PC20-based prediction of allergen PC20 (using methacholine) and a new methacholine PC20-based prediction equation.
Methods: From 158 allergen challenges, the allergen PC20, the methacholine PC20, and the skin test endpoint were recorded and relationships between these three were sought. We compared the measured allergen PC20 to that predicted from the previous histamine PC20-based and the new methacholine-based formulae.
Results: In single regressions, allergen PC20 correlated with both methacholine PC20 (r=0.25, P=0.0015) and skin test endpoint (r=0.52, P <0.00005). The relationship was improved by multiple regression of log-allergen PC20vs. log-methacholine PC20 and log-endpoint (r=0.61, P <0.00005). The histamine-based formula predicted allergen PC20 to within 2 doubling concentrations in 80% and within 3 in 92%. The new methacholine-based formula to within 2 and 3 concentrations in 81% and 94%, respectively; only nine of 158 subjects were outside the 3 concentrations.
Conclusions: We have confirmed the dependence of the allergen-induced early asthmatic response upon the level of allergic sensitivity and the degree of AHR, the latter as assessed by methacholine challenge. The allergen PC20 can be predicted to within 3 doubling concentrations in 94% of cases.
Similar articles
-
Bronchial responsiveness to bakery-derived allergens is strongly dependent on specific skin sensitivity.Allergy. 2006 Oct;61(10):1202-8. doi: 10.1111/j.1398-9995.2006.01189.x. Allergy. 2006. PMID: 16942570
-
Validated safety predictions of airway responses to house dust mite in asthma.Clin Exp Allergy. 2007 Jan;37(1):100-7. doi: 10.1111/j.1365-2222.2006.02617.x. Clin Exp Allergy. 2007. PMID: 17210047
-
Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine.Am Rev Respir Dis. 1987 Jan;135(1):264-7. doi: 10.1164/arrd.1987.135.1.264. Am Rev Respir Dis. 1987. PMID: 3800152
-
[Allergic inflammation in the development of nonspecific bronchial hyperresponsiveness in asthma].Pol Merkur Lekarski. 2002 Jun;12(72):515-8. Pol Merkur Lekarski. 2002. PMID: 12362673 Review. Polish.
-
Airway hyperresponsiveness as a determinant of the early asthmatic response to inhaled allergen.J Asthma. 2006 Apr;43(3):175-8. doi: 10.1080/02770900600566348. J Asthma. 2006. PMID: 16754517 Review. No abstract available.
Cited by
-
Natural-source d-α-tocopheryl acetate inhibits oxidant stress and modulates atopic asthma in humans in vivo.Allergy. 2012 May;67(5):676-82. doi: 10.1111/j.1398-9995.2012.02810.x. Epub 2012 Mar 22. Allergy. 2012. PMID: 22435735 Free PMC article. Clinical Trial.
-
Structure and function of small airways in asthma patients revisited.Eur Respir Rev. 2021 Jan 19;30(159):200186. doi: 10.1183/16000617.0186-2020. Print 2021 Mar 31. Eur Respir Rev. 2021. PMID: 33472958 Free PMC article. Review.
-
Allergen inhalation challenge, refractoriness and the effects of ibuprofen.Allergy Asthma Clin Immunol. 2016 May 24;12:24. doi: 10.1186/s13223-016-0127-z. eCollection 2016. Allergy Asthma Clin Immunol. 2016. PMID: 27222654 Free PMC article.
-
Rethinking Meta-Analysis: Applications for Air Pollution Data and Beyond.Risk Anal. 2015 Jun;35(6):1017-39. doi: 10.1111/risa.12405. Epub 2015 May 13. Risk Anal. 2015. PMID: 25969128 Free PMC article.
-
Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.Eur Respir J. 2024 Sep 12;64(3):2400512. doi: 10.1183/13993003.00512-2024. Print 2024 Sep. Eur Respir J. 2024. PMID: 39060015 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical